Clinical efficacy and safety of herbal medicine Dermidoc in the management of atopic dermatitis versus allopathic medicine PolymixinB-bacitrin ointment.
Atopic dermatitis (AD) commonly identified as eczema. AD is an inflammatory, long-lasting, highly pruritic reverting disease of the skin. AD is classified by disease of outer skin layer barrier function. AD is progress with Immunoglobulin E facilitated sensitization to food and environmental allergens. One study stated that more than 59.6% of teen-agers with AD are at high risk of develop asthma or rhinitis. Interaction between genes and environment increase the prevalence of AD. AD have three standard stages: infantile, childhood, and adulthood. AD sign and symptoms diverge extensively. AD can be present that simply affect the hand to where a patient presents with erythroderma. AD present with erythematous papules, extremely pruritic with serous exudate. Lichenified plaques and papules are symptoms of long lasting AD. Due to outer skin layer barrier dysfunction bacterial and viral infection risk is increased in AD patients. This study was directed on 100 patients in which 50 are PolymixinB-bacitrin group and 50 are Dermidoc group. Patients were selected after seeing inclusion and exclusion criteria and taking written informed consent. Dermidoc group expressively amended skin symptoms associated with AD comparing to the PolymixinB-bacitrin group. The Dermidoc cream is effective and well tolerated. The results were analysis using paired sample t-test. The p value is <0.05. Test group (Dermidoc) were significantly more effective than PolymixinB-bacitrin group.
Hamdard Al Majeed College of Eastern Medicine, Faculty of Eastern Medicine, Karachi, Pakistan.
Muhammad Osama
MO
Alam
Hamdard Al Majeed College of Eastern Medicine, Faculty of Eastern Medicine, Karachi, Pakistan.
Ejaz
E
Mohiuddin
Hamdard Al Majeed College of Eastern Medicine, Faculty of Eastern Medicine, Karachi, Pakistan.
-
-
Shahab-Ud-Din
Department of Medical Affairs and Training, Department of Research and Development, Herbion Pharmaceutical (Pvt.) Limited, Karachi, Pakistan.
Muhammad
M
Daniyal
Department of Medical Affairs and Training, Department of Research and Development, Herbion Pharmaceutical (Pvt.) Limited, Karachi, Pakistan.
Khan
K
Usmanghani
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000009:adverse effects; D001414:Bacitracin / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000008:administration & dosage* / Q000009:adverse effects; D028321:Plant Preparations / Q000008:administration & dosage* / Q000009:adverse effects; D011112:Polymyxin B / Q000008:administration & dosage* / Q000009:adverse effects; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D055815:Young Adult
D000891:Anti-Infective Agents, Local; C000621520:DermiDoc; D010936:Plant Extracts; D028321:Plant Preparations; C069612:bacitracin, polymyxin B drug combination; D001414:Bacitracin; D011112:Polymyxin B